Saturday, June 17, 2023
Cholesgen has recently announced a three-year collaboration with AstraZeneca to advance research and development in hypercholesterolaemia and related metabolic diseases.
During this collaboration, Cholesgen and AstraZeneca will combine their strengths and expertise to focus on selected targets from Cholesgen's early-stage portfolios. Cholesgen will receive an initial payment and a pre-defined licence package for each qualified drug candidate nominated by AstraZeneca to proceed into clinical development.
This collaboration between Cholesgen and AstraZeneca aims to achieve two primary objectives such as validating genetic drug targets and advancing therapeutic molecules into clinical development.
By combining their efforts and expertise, the partnership has the potential to expedite the development of groundbreaking medicines that will bring significant benefits to patients suffering from hypercholesterolemia and related metabolic diseases.
A joint research committee oversees the efforts of both Cholesgen and AstraZeneca researchers to ensure effective collaboration and work closely together on target validation and target generation to identify promising drug candidates.
